NATF is busy planning for the September 20, 2014 Thrombosis Summit and is reaching out to communities this summer from Winchester, MA to Cape Cod to educate and advocate about thrombosis. We are in the midst of our 2014 Membership Drive and are planning the roll-out of our 2014 Annual Fund Campaign.
With this exponential increase in activity, we will announce in my August 2014 Letter the hiring of two new full-time NATF staff members. These talented individuals will triple our staff from 1 (Erica Dour, Associate Director) to 3.
Click here to read the full letter.
Participate in NATF's largest educational event, the Annual Thrombosis Summit, on Saturday, September 20, 2014! Check back soon for details and registration information.
NATF has collaborated with the Patient Centered Outcomes Research Institute (PCORI), and the Johns Hopkins Medicine Institutional Review Board, to embark on an important project to build patient education for the prevention of venous thromboembolism (VTE). Scroll down to participate in this project!
Atrial Fibrillation in Patients with Cryptogenic Stroke
New England Journal of Medicine: 26 June 2014
The prevention of stroke related to atrial fibrillation is a global public health priority. Strokes due to atrial fibrillation are common and frequently devastating (70 to 80% of patients die or become disabled1,2), yet they are largely preventable with anticoagulant therapy (64% reduction in the risk of stroke and 25% reduction in mortality).3 However, because atrial fibrillation is often intermittent and asymptomatic, it can be a silent risk factor that easily evades detection.4,5
Since patients who have had a stroke or transient ischemic attack (TIA) due to atrial fibrillation face a high annual risk of stroke recurrence,6 strategies to improve the detection and treatment of atrial fibrillation promise to reduce the burden of recurrent strokes. In the absence of atrial fibrillation, the standard treatment for secondary prevention of stroke is antiplatelet therapy; however, when atrial fibrillation is present, antiplatelet therapy is only modestly effective (22% reduction in risk, as compared with placebo),3 and anticoagulation is strongly recommended instead (39%3 to 63%7 reduction in the risk of stroke as compared with antiplatelet therapy). Currently, 1 in 6 strokes is attributed to atrial fibrillation, but 1 in 4 of the estimated 12 million ischemic strokes annually (and half the TIAs) has no cause identified after a standard diagnostic workup and is labeled “cryptogenic.”8,9 Undiagnosed atrial fibrillation is often suspected as the cause of many cryptogenic strokes, but anticoagulation is not recommended unless atrial fibrillation has been documented.
An unsolved problem is how to detect “covert” atrial fibrillation in patients with stroke. Screening is typically limited to electrocardiographic (ECG) monitoring for a short period (e.g., 24 hours), which is not sufficiently sensitive for the detection of paroxysmal atrial fibrillation10-12; as a result, it is likely that atrial fibrillation is being routinely underdiagnosed and undertreated with this approach.
Read the full article here.
Venous Thromboembolism Prevention Assessment
NATF has collaborated with the Patient Centered Outcomes Research Institute (PCORI), and the Johns Hopkins Medicine Institutional Review Board, to embark on an important project to build patient education for the prevention of venous thromboembolism (VTE).
This project is comprised of a series of up to 5 Web-based surveys. This first survey will ask some background information. Your input in this assessment is very important, but is also completely voluntary.
What does working as a Page at the Georgia Senate mean to us?
In this new eThrombosis article, Georgia young advocates explain the PAGE Program at the Georgia State Capitol, and describe their experience participating in the lawmaking process.
Read the full article here!
Pradaxa(R) (dabigatran etexilate) Now Available in the UK for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) and Prevention of Recurrence
Wall Street Journal MarketWatch: 15 July 2014 - DVT and PE are dangerous conditions, with over 25,000 deaths estimated to occur in hospitalised patients each year in the UK.3 Pradaxa(R) gained approval from the European Medicines Agency (EMA) in early June and was granted approval for the same indication by the U.S. Food and Drug Administration earlier this year.4
Read more here.
XALIA: rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein thrombosis
Thrombosis Journal: 14 July 2014 - Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism, poses a substantial clinical risk, and the incidence of these thrombotic-related diseases remains high. Anticoagulation aims to prevent thrombus extension and reduce the risk of recurrent events, particularly fatal pulmonary embolism. In EINSTEIN DVT, rivaroxaban was non-inferior to enoxaparin/vitamin K antagonists for the reduction of recurrent VTE, with a similar safety profile and a net clinical benefit.
Read more here.
Danger, Diagnosis & Treatment of Pulmonary Embolism
Everyday Health: 30 June 2014 - The call initially seemed simple: A 67-year-old man who had a near-syncopal episode in church. By the time the first-response engine and paramedic crew arrived on scene, the man was feeling better and declined transport to a hospital. But to te. he two East Texas Medical Center paramedics, the patient looked far too sick to be let go. When they stood him up he started to faint again and became significantly tachycardic and hypotensive.
Read the article here.